# DoD Gulf War Illness, Research Advancement Award

Source: https://welltoldgrants.com/grants/w81xwh-21-gwirp-raa-dod-gulf-war-illness-research-advancement-award/  
Official notice: https://www.grants.gov/search-results-detail/332036

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 2 awards worth $1.9 million in total. Applications closed on August 19, 2021.

| Field | Value |
|---|---|
| Opportunity number | W81XWH-21-GWIRP-RAA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | August 19, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 2 |
| Total funding | $1.9 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The FY21 GWIRP Research Advancement Award supports applied research in GWI that is aimed at continued expansion and validation of markers and treatments that are supported by evidence in the GWI field. The Research Advancement Award targets the Qualification phase of the research pipeline as outlined in Section II.A.2. Preliminary Data: Inclusion of preliminary data in the field of GWI and other supporting information is required. The project should include a well-formulated, testable hypothesis based on existing evidence in the GWI field that holds translational potential. Impact: Applications must articulate how results will lead to a clinical impact for Veterans with GWI even if a clinical impact is not an immediate outcome. All applications must focus on features of GWI and Veterans of the 1990-1991 Gulf War affected by GWI. The application should clearly and explicitly articulate the project’s potential impact on GWI. The types of activities supported include 1) expansion of limited data on candidate markers, mechanistic targets, therapeutics, or other interventions; 2) replication of druggable mechanistic targets, further development of leading compounds, or the collection of preclinical data for repurposing an existing approved drug or for new Investigational New Drug (IND) application submissions to the U.S. Food and Drug Administration (FDA). Applicants proposing to test FDA-approved drugs in animal models for efficacy must explain why preclinical testing is required prior to clinical pilot trials in humans. FY21 GWIRP Research Advancement Award Areas of Emphasis: The FY21 GWIRP Research Advancement Award has a special interest in the exploration of the topics listed below. Applicants are not restricted to this list and may propose studies in any other GWI research area relevant to the mission of the GWIRP and in the context of the FY21 GWIRP Overarching Challenges. • Replication and/or validation of treatments for GWI, particularly areas that already show positive impact on the disease • Expeditiously advancing and translating new and promising areas of GWI understanding • Replication and/or validation of the causes of and treatment targets for dysregulated biological system function.

## Questions people ask

### Is W81XWH-21-GWIRP-RAA still open?

No. It closed on August 19, 2021. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Gulf War Illness, Research Advancement Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Gulf War Illness, Research Advancement Award?

Closed August 19, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $1.9 million in total across about 2 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.